There was also a decreasing trend in the number of patients using biologic treatments, from 15 patients before AIT, mainly omalizumab (n = 14), to none at five years ( Figure 2 ).
← all excerpts
Safety and Effectiveness of Allergen Immunotherapy in Patients with Severe Allergic Asthma.
1
—
—